Success Metrics

Clinical Success Rate
20.0%

Based on 1 completed trials

Completion Rate
20%(1/5)
Active Trials
0(0%)
Results Posted
500%(5 trials)
Terminated
4(80%)

Phase Distribution

Ph phase_2
2
40%
Ph phase_3
3
60%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

20.0%

1 of 5 finished

Non-Completion Rate

80.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(1)
Terminated(4)

Detailed Status

Terminated4
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
20.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (40.0%)
Phase 33 (60.0%)

Trials by Status

completed120%
terminated480%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_3

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT02247531
completedphase_2

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

NCT02288559
terminatedphase_2

An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy

NCT01602120
terminatedphase_3

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT02247479
terminatedphase_3

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)

NCT02745119

Clinical Trials (5)

Showing 5 of 5 trials
NCT02247531Phase 3

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Terminated
NCT02288559Phase 2

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

Completed
NCT01602120Phase 2

An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy

Terminated
NCT02247479Phase 3

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Terminated
NCT02745119Phase 3

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5